Received Apr 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| YF | YELLOW FEVER (YF-VAX) | SANOFI PASTEUR | UNK | UK324AB | SC / LA |
had received a Yellow Fever Vaccine, later it was confirmed they received Stamaril in 2020, with no reported adverse event; Initial information received on 02-Apr-2026 regarding an unsolicited valid non-serious case received from a nurse. This case involves a 17 years old male patient who had received a yellow fever vaccine (YF-VAX), later it was confirmed they received Stamaril in 2020, with no reported adverse event. The patient's past medical history, medical treatment(s), family history were not provided. The patient had past vaccination included Stamaril in 2020 On 28-Mar-2026, the patient received a 0.5 mL once dose of yellow fever vaccine [YF-VAX] solution for injection (batch/lot number: UK324AB, expiry date: 30-Nov-2026) (strength: unknown) via subcutaneous route in left arm for immunization. Nurse stated that they vaccinated a family of 4 with YF-VAX. At that time the family was not aware that they had received a yellow fever vaccine. Later it was confirmed they received Stamaril in 2020 (Extra dose administered, onset: 28-Mar-2026, latency: same day). Nurse would like safety information related to a second vaccination. Action taken: Not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Comments: NONE